Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sean Burnett

Physician Assistant Jamaica, NY Physician Assistant

NPI 1891893558 CMS profile 10963716

8900 Van Wyck Expy, Emergency Department, Jamaica, NY 11418

Open in the dashboard

General payments

$9,470

301 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sean Burnett of Jamaica, NY is reported in the CMS Open Payments database as having received $9,470 across 301 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,260 49
2024 General $1,403 46
2023 General $1,815 74
2022 General $1,324 57
2021 General $1,667 75

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sean Burnett
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Sean Burnett were reported at $3,260. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Sean Burnett Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,667 $132 $37–$438 $132
2022 $1,324 $155 $48–$522 $149
2023 $1,815 $167 $52–$557 $160
2024 $1,403 $178 $55–$600 $164
2025 $3,260 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,678 68 payments
  2. Madrigal Pharmaceuticals $2,359 26 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,743 112 payments
  4. Gilead Sciences, Inc. $631 28 payments
  5. Janssen Biotech, Inc. $473 9 payments
  6. Ardelyx, Inc. $473 10 payments
  7. RedHill Biopharma Inc. $298 15 payments
  8. Cumberland Pharmaceuticals, Inc. $243 7 payments
  9. Ironwood Pharmaceuticals, Inc $146 7 payments
  10. Intercept Pharmaceuticals, Inc. $125 1 payment
  11. Other $302 18 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,225 297 payments
  2. Consulting Fee $1,080 1 payment
  3. Education $165 3 payments
Products named General payments · program years 2021–2025
  1. REZDIFFRA $2,295 24 payments
  2. MAVYRET $1,747 38 payments
  3. XIFAXAN $996 73 payments
  4. TRULANCE $868 52 payments
  5. IBSRELA $473 10 payments
  6. SKYRIZI $316 9 payments
  7. CREON $316 11 payments
  8. TREMFYA $308 3 payments
  9. Talicia $298 15 payments
  10. KRISTALOSE $243 7 payments
  11. Other $2,140 86 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

4,203

Median for Physician Assistant: 241

Drug cost

$648,898

Median for Physician Assistant: $4,110

Branded share of claims

29.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 78 $273,494
Linzess Linaclotide Brand 408 $218,996
Xifaxan Rifaximin Brand 15 $39,627
Trulance Plecanatide Brand 65 $35,312
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 413 $22,356
Ozempic Semaglutide Brand 19 $17,368
Lubiprostone Generic 22 $4,968
Mesalamine Generic 16 $4,250
Pantoprazole Sodium Generic 714 $3,715
Famotidine Generic 672 $3,670

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MAVYRET
  • AbbVie, Inc. $339
$339 — —
IBSRELA
  • Ardelyx, Inc. $240
$240 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $166
$166 15 —
SKYRIZI
  • AbbVie, Inc. $163
$163 — —
TRULANCE
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $76
$76 65 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

301 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record